Last Price Today's Change   Day's Range   Trading Volume
0.028   -0.001 (3.45%)  0.028 - 0.03  8,722,375


Avg Volume (4 weeks):21,082,708
4 Weeks Range:0.027 - 0.04
4 Weeks Price Volatility (%):
52 Weeks Range:0.012 - 0.04
52 Weeks Price Volatility (%):
Average Price Target:-


No recent Headlines for this stock.

Business Background

Imugene Limited is an immuno-oncology focused biopharmaceutical company. The Company is engaged in the research and development of human epidermal growth factor receptor 2 positive (HER2 +ve), and gastric and breast cancer vaccines. The Company is also engaged in the research, development and commercialization of health technologies. HER-Vaxx is a cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has completed a Phase I clinical trial with over 10 HER-2 positive patients with metastatic breast cancer. It was shown in pre-clinical studies and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu. HER-Vaxx has stimulated the production of HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. The Company is also developing mimotope-based immunotherapies against validated and oncology targets.

  Be the first to like this.


531  685  688  9258 

Top 10 Active Counters
 AGO 0.030.00 
 PCH 0.0030.00 
 LKO 0.0030.00 
 AEE 0.024-0.003 
 AOA 0.0190.00 
 QBL 0.052-0.002 
 ANW 0.022+0.005 
 CLYO 0.0020.00 
 GLA 0.0060.00 
 BD1 0.018+0.003 
Partners & Brokers